Business Wire

CA-LINKSYS

13.9.2023 22:48:28 CEST | Business Wire | Press release

Share
Linksys Announces the Next Step in Home and Small Office Connectivity

Linksys®, an iconic Home and Small Office connectivity company, announces in a statement of direction its new Cognitive Experience technology. Cognitive Experience brings a whole new level of intelligence to networking with cutting-edge technological features specially designed to enhance and improve the user experience.

In the technology space, the word “cognitive” refers to “thinking technologies” that can deterministically – either by user selection or automation – solve problems. Developed based on user input and feedback, Cognitive Experience focuses on saving time and effort by automating the process for reporting technical issues to customer support agents.

“Currently 50% of our Support calls are dead air, nobody talking, as our Guardians review the logs and network information while the customer is on the phone,” said Lucas Peterson, Head of Product Support at Linksys. “With Linksys Cognitive Experience, we get all the information we need sent upfront through automation so that our Guardians can review and diagnose before they call the customer. This coupled with our ability to temporarily co-administer the network — with the customer’s permission, of course — will enable us to solve problems in lightning-fast time.”

Cognitive Experience allows a Linksys customer service agent to analyze your technical issue remotely, so that when they contact the user, they have all the information necessary to address the problem. Customer service agents can then administer tech support remotely through your network. You’re able to grant or rescind access to the network at any time. This allows customer service agents to effectively tackle any issues in lightning-fast time.

In Phase 1 of its implementation, Cognitive Experience features will focus on the following:

  • If you experience a problem with your WiFi network, Cognitive Experience is able to run a test on your network
  • Open a trouble-ticket from the Linksys App and get a call from Linksys customer service agents
  • An agent will review the report and can easily access your network, with your permission, to address the problem
  • Cognitive Experience will run a health check on your network to locate any additional potential issues

Phase 1 of Linksys Cognitive Experience is set to be completed by the end of this calendar year. Cognitive Experience will make its debut with products in the Linksys Designer Series through the end of the year. Starting in 2024, Cognitive Experience will be available in other Linksys products.

Phase 2 of Linksys Cognitive Experience is currently under development and includes new “intelligent notifications” that humanize or personalize the insights derived from your network, delivered in a meaningful way.

Examples of intelligent notifications include:

  • When a network’s WAN goes down, we verify the Home Network is operating and then send a WAN Down notification
  • When a network’s WAN comes back up, we verify it and retest the Home Network and send WAN Up and Home Network Up notifications
  • Users can select certain devices to be notified when they leave and rejoin the network

Designer Series offerings that include Cognitive Experience are:

  • Velop Pro 6E – currently available in the US at Amazon, Best Buy and Linksys.com
  • Velop Pro 7 – expected in September/October, now available for pre order at Amazon and Best Buy
  • Velop Micro Router 6 – expected in October/November
  • Velop Micro Mesh 6 – expected in October/November

About Linksys

At Linksys, we engineer simplicity so that you never experience complexity. Linksys is an iconic brand celebrating its 35th year of innovation in Home and Small Office connectivity. With many industry firsts to its credit, Linksys delivers simple, fast, reliable, and affordable products for the Home and Small Office where there is “no IT.”

© 2023 Linksys Holdings, Inc. and/or its affiliates. All rights reserved.

Linksys and many product names and logos are trademarks of Linksys Holdings Inc. and/or its affiliates. Third-party trademarks mentioned are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230913706425/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release

Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye